Novo Nordisk A/S-BNONOF
13F holders, Q3 2025 (September 30)3holders
2new positions
1sold out
$54.23avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, unchanged from Q2 2025. 2 opened new positions and 1 sold out. The largest holders were Saranac Partners Ltd ($729K), LBMC Investment Advisors, LLC ($393K) and Steigerwald, Gordon & Koch Inc. ($3K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $732K |
| Exits | 1 | $42.3M |
All 13F filers, Q2 2025 → Q3 2025: 13,491 shares bought and 609,460 shares sold, net −595,969 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Saranac Partners Ltd | 0.15% | New | 13,431 | $729K |
| LBMC Investment Advisors, LLC | 0.03% | No change | 7,250 | $393K |
| Steigerwald, Gordon & Koch Inc. | 0.00% | New | 60 | $3K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.